Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03299543 · ClinicalTrials.gov registry record

Comparison Between Breath Acetone and Blood Beta-Hydroxybutyrate

A clinical trial of Ketosis, sponsored by Medamonitor.

Completed
Registry status
61
Enrollment target
1
Study location

NCT03299543: Completed study of Ketosis, sponsored by Medamonitor.

NCT03299543 is a study of Ketosis that has completed, run by Medamonitor. The registered enrollment target is 61 participants, below the 116-participant average among 4 other Ketosis trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03299543, a study of Ketosis, has completed, sponsored by Medamonitor.

COMPLETED
Registry status
61 participants
Enrollment target
1
Study location

Study Summary

Subjects will provide blood and breath samples to evaluate the relationship between breath acetone and two blood-bound species: beta-hydroxybutyrate and glucose. Subjects will be asked to provide breath and blood samples at a baseline visit and second optional visit. The two visits will be spaced approximately 3 hours apart.

Primary Outcome

Both individual and average group measurements will be compared

Conditions Studied

Interventions

  • DEVICE LEVL (Medamonitor)

Study Locations (1)

Washington

  • Medamonitor, LLC - Seattle

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2017-09-12
Est. Completion 2018-02-28
Medamonitor

1 total trials

What the finished NCT03299543 record still lists

NCT03299543 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 61 participants, a relatively small participant target, below the 116-participant average among 4 other Ketosis trials with a reported enrollment target (47% lower).

The record links to 1 condition, with Ketosis appearing as the primary indexed condition, and to 1 intervention - of which LEVL (Medamonitor) is the first listed.

NCT03299543 reports a single indexed study location in Washington.

Frequently Asked Questions

What is clinical trial NCT03299543 about?

NCT03299543 is a clinical study titled "Comparison Between Breath Acetone and Blood Beta-Hydroxybutyrate". Subjects will provide blood and breath samples to evaluate the relationship between breath acetone and two blood-bound species: beta-hydroxybutyrate and glucose. Subjects will be asked to provide breath and blood samples at a baseline visit and second optional visit. The two visits will be spaced ap...

What is the current status of trial NCT03299543?

This trial is currently completed. The enrollment target is 61 participants. The study started on 2017-09-12. Estimated completion is 2018-02-28.

What conditions does trial NCT03299543 study?

This clinical trial studies the following conditions: Ketosis.

What interventions are being tested in trial NCT03299543?

The interventions under investigation include: LEVL (Medamonitor) (DEVICE).

Who is sponsoring clinical trial NCT03299543?

This trial is sponsored by Medamonitor, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03299543 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ketosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04115306 · 61 participants · Phase 1

    Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

  • NCT05070845 · 61 participants · Phase 2

    Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

  • NCT05187832 · 61 participants · Phase 1

    A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

  • NCT05269316 · 61 participants · Phase 1

    Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03299543, the US trial registry maintained by the National Library of Medicine. NCT03299543 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.